Business Context and Reporting Period
This Form 8-K reports on events occurring on May 27, 2015, specifically the Annual Meeting of Stockholders for Amphastar Pharmaceuticals, Inc. The filing details the election of directors, the approval of a new equity incentive plan, and the ratification of the independent auditor.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the formal adoption of the 2015 Equity Incentive Plan following stockholder approval. Additionally, the Board composition was updated with the election of three Class II directors.
Guidance, Outlook, and Voting Results
The filing provides no management guidance, outlook, or discussion of risks and contingencies. It details the following voting outcomes from the Annual Meeting:
- Election of Directors: All three nominees (Mary Ziping Luo, Michael A. Zasloff, and Howard Lee) were elected. Broker non-votes totaled 3,420,926 for each nominee.
- 2015 Equity Incentive Plan: Approved by stockholders with 25,137,826 votes "For" and 5,961,033 votes "Against".
- Auditor Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2015, with 33,879,084 votes "For".
Investor Verification Checklist
- Verify the specific terms and share limits of the newly approved 2015 Equity Incentive Plan (Exhibit 10.1).
- Confirm the tenure of the newly elected Class II directors (serving until the 2018 annual meeting).
- Review the Proxy Statement dated April 8, 2015, for detailed descriptions of the equity plan terms referenced in this filing.